Nasdaq · Healthcare
Silence Therapeutics plc (SLN)
As-reported financials and recent SEC filings for Silence Therapeutics plc, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$559,000
Net income
$-88.6M
Net margin
—
Diluted EPS
$-0.63
ROE
-142.2%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2024 | FY2024 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $559,000 | $43.3M | $31.6M | $21.7M | — |
| Gross profit | $344,000 | $31.4M | $18.8M | $8.2M | — |
| Operating income | $-91.1M | $-63.3M | $-64.4M | $-61.0M | — |
| Net income | $-88.6M | $-45.3M | $-54.2M | $-50.3M | — |
| Diluted EPS | $-0.63 | $-0.33 | $-0.49 | $-0.52 | — |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-23
View on EDGAR →8-K2026-06-16
View on EDGAR →8-K2026-06-11
View on EDGAR →EFFECT2026-05-27
View on EDGAR →424B52026-05-27
View on EDGAR →8-K2026-05-18
View on EDGAR →S-32026-05-18
View on EDGAR →10-Q2026-05-07
View on EDGAR →Largest Healthcare peers
Go deeper on SLN
Search Silence Therapeutics plc’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.